The European Investment Bank (EIB) has signed a €30 million convertible loan agreement with Amsterdam-based VectorY Therapeutics, a clinical-stage biotechnology company developing a novel treatment for neurodegenerative diseases. The financing, supported by the European Commission’s InvestEU programme, will help accelerate the development of VectorY’s vectorised antibody platform, which can help to better treat neuro-degenerative diseases, and expand its pipeline. The EIB financing is part of a broader financing syndicate comprised of new investors and existing shareholders.